Pancreatic cancer

Thomas F. Stoop; Ammar A. Javed; Atsushi Oba; Bas Groot Koerkamp; Thomas Seufferlein; Johanna W. Wilmink; Marc G. Besselink

doi:10.1016/S0140-6736(25)00261-2

Pancreatic cancer

Thomas F. Stoop, Ammar A. Javed, Atsushi Oba, Bas Groot Koerkamp, Thomas Seufferlein, Johanna W. Wilmink, Marc G. Besselink^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Review article › Academic › peer-review

10 Citations (Scopus)

Abstract

Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.

Original language	English
Pages (from-to)	1182-1202
Number of pages	21
Journal	The Lancet
Volume	405
Issue number	10485
DOIs	https://doi.org/10.1016/S0140-6736(25)00261-2
Publication status	Published - 5 Apr 2025

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(25)00261-2

Cite this

@article{656483354c0347e2a5408d031b549b2a,

title = "Pancreatic cancer",

abstract = "Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.",

author = "Stoop, {Thomas F.} and Javed, {Ammar A.} and Atsushi Oba and Koerkamp, {Bas Groot} and Thomas Seufferlein and Wilmink, {Johanna W.} and Besselink, {Marc G.}",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Ltd",

year = "2025",

month = apr,

day = "5",

doi = "10.1016/S0140-6736(25)00261-2",

language = "English",

volume = "405",

pages = "1182--1202",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10485",

}

TY - JOUR

T1 - Pancreatic cancer

AU - Stoop, Thomas F.

AU - Javed, Ammar A.

AU - Oba, Atsushi

AU - Koerkamp, Bas Groot

AU - Seufferlein, Thomas

AU - Wilmink, Johanna W.

AU - Besselink, Marc G.

PY - 2025/4/5

Y1 - 2025/4/5

N2 - Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.

AB - Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=105001595770&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(25)00261-2

DO - 10.1016/S0140-6736(25)00261-2

M3 - Review article

C2 - 40187844

AN - SCOPUS:105001595770

SN - 0140-6736

VL - 405

SP - 1182

EP - 1202

JO - The Lancet

JF - The Lancet

IS - 10485

ER -

Pancreatic cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Embargoed Document

Fingerprint

Cite this